

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Any. Docket No. 28967/35255A	Serial No. 09/375,246
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
		Applicant Ferrell et al.	
		Filing Date 8-16-99	Group 1633

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date/ Publication Date	Name	Class	Subclass	Filing Date If Appropriate
11	A9	6,040,157	3-21-00	Hu, et al.	435	69.4	
11	A10	2003/0028007	2-6-03	Hu, et al.	536	23.5	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation
11	B5	WO 99/46364	9-16-99	WIPO			
	B6	WO 01/51075	7-19-01	WIPO			
	B7	WO 02/29087	4-11-02	WIPO			
	B8	WO 02/83704	10-24-02	WIPO			
11	B9	WO 02/83849	10-24-02	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER 11	DATE CONSIDERED 04/16/03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
<i>FE</i>	A1	5,002,867	03/26/91	Macevicz, S.C.	435	6	
	A2	5,143,854	09/01/92	Pirrung, M.C. <i>et al.</i>	436	518	
	A3	5,202,231	04/13/93	Drmanac, R.T. <i>et al.</i>	435	6	
	A4	5,521,065	05/28/96	Whiteley, N.M. <i>et al.</i>	435	6	
	A5	5,631,237	05/20/97	Dzau, V.J. <i>et al.</i>	514	44	
	A6	5,776,755	07/07/98	Alitalo, K. <i>et al.</i>	435	194	
	A7	5,792,453	08/11/98	Hammond, H.K. <i>et al.</i>	424	93.21	
<i>FE</i>	A8	5,837,832	11/17/98	Chee, M. <i>et al.</i>	536	22.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
<i>FE</i>	B1	WO 98/33917	08/06/98	WIPO				
<i>FE</i>	B2	WO 98/07832	02/26/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

<i>FE</i>	C1	Achen <i>et al.</i> , "Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci., USA</i> , 95: 548-553 (January, 1998).
-----------	----	---

EXAMINER

Boiselle

DATE CONSIDERED

2/14/01 *Jy 07*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group 1632

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C2	Akane <i>et al.</i> , "Direct Dideoxy Sequencing of Genomic DNA by Ligation-Mediated PCR," <i>Biotechniques</i> 16: 238-241 (1994).
C3	Aprelikova <i>et al.</i> , "FLT4, a Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," <i>Cancer Res.</i> , 52: 746-748 (1992).
C4	Barrowman, J.A., "Gastrointestinal Lymphatics," in <i>Lymph Stasis: Pathophysiology, Diagnosis and Treatment</i> , Chapter 9, CRC Press, Boca Raton, FL, pp. 211-231 (1991).
C5	Boshart <i>et al.</i> , "A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," <i>Cell</i> , 41:521-530 (June, 1985).
C6	Boultonwood <i>et al.</i> , "Molecular Mapping of Uncharacteristically small 5q deletions in two patients with the 5q-syndrome: Delineation of the critical region on 5q and identification of a 5q-breakpoint," <i>Genomic</i> , 19(3):425-432 (1994).
C7	Browman <i>et al.</i> , "Comprehensive Human Genetic Maps: Individual and Sex-Specific Variation in Recombination," <i>Am. J. Hum. Genetic.</i> , 63:861-869 (1998).
C8	Campbell-Beggs <i>et al.</i> , "Chyloabdomen in a neonatal foal," <i>Veterinary Record</i> , 137: 96-98 (July, 1995).
C9	Castenholz, A., "Structure of Initial and Collecting Lymphatic Vessels," in <i>Lymph Stasis: Pathophysiology, Diagnosis, and Treatment</i> , Chapter 2, CRC Press: Boca Raton, FL, pp.15-42 (1991).
C10	Dale, R.F., "The Inheritance of Primary Lymphoedema," <i>J. Med. Genet.</i> , 22: 274-278 (1985).
C11	Davis <i>et al.</i> , "Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression," <i>Hum. Gene Ther.</i> , 4:151-159 (1993).
C12	Dignam <i>et al.</i> , "Balbiani Ring 3 in Chironomus tentans Encodes a 185-kDa Secretory Protein Which is Synthesized Throughout the Fourth Larval Instar," <i>Gene</i> , 88:133-40 (1990).
C13	Douglas <i>et al.</i> , "Direct Sequencing of Double-Stranded PCR Products Incorporating a Chemiluminescent Stection Procedure," <i>Biotechniques</i> , 14:824-828 (1993).
C14	Drmanac, S. <i>et al.</i> , "Accurate sequencing by hybridization for DNA diagnostics and individual genomics," <i>Nature Biotechnology</i> , 16: 54-58 (January, 1998)

EXAMINER

R. Ferrell

DATE CONSIDERED

2/14/01 J. L. 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group 1632

(Use several sheets if necessary)

JAN 13 2000

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C15	Dumont <i>et al.</i> , "Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3," <i>Science</i> , 282: 946-949 (October, 1998).
C16	Evans, A.L. <i>et al.</i> , "Mapping of Primary Congenital Lymphedema to the 5q35.3 Region," <i>Am. J. Hum. Genet.</i> , 64:547-555 (1999).
C17	Ferrell <i>et al.</i> , "Hereditary lymphedema: evidence for linkage and genetic heterogeneity," <i>Hum. Mol. Genetics</i> , 7(13):2073-2078 (December, 1998).
C18	Fischer <i>et al.</i> , "DNA Fragments Differing by Single Base-Pair Substitutions are Separated in Denaturing Gradient Gels: Correspondence with Melting Theory," <i>Proc. Natl. Acad. Sci., USA</i> , 80: 1579-1583 (March, 1983).
C19	Fournier <i>et al.</i> , "Mutation in tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor," <i>Oncogene</i> , 11(5):921-931 (1995).
C20	Fournier <i>et al.</i> , "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling," <i>Oncogene</i> , 18(2):507-514 (January, 1999).
C21	Fox, J.C. <i>et al.</i> , "Angiogenic Gene Therapy," <i>Circulation</i> , 94:3065-3066 (1996).
C22	Galland <i>et al.</i> , "Chromosomal Localization of <i>FLT4</i> , a Novel Receptor-Type Tyrosine Kinase Gene," <i>Genomics</i> , 13: 475-478 (1992).
C23	Galland <i>et al.</i> , "The FLT4 Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," <i>Oncogene</i> , 8: 1233-1240 (1993).
C24	Genbank Accession No. AF014827, <i>Rattus norvegicus</i> vascular endothelial growth factor D (VEGF-D) mRNA, complete cds.
C25	Genbank Accession No. AJ000185, <i>Homo Sapiens</i> mRNA for vascular endothelial growth factor-D.
C26	Genbank Accession No. CCY15837, <i>Coturnix coturnix</i> mRNA for vascular endothelial growth factor C.
C27	Genbank Accession No. D89628, <i>Mus musculus</i> mRNA for vascular endothelial growth factor D, complete cds.
C28	Genbank Accession No. L07296, <i>Mus musculus</i> receptor tyrosine kinase (FLT4) mRNA, complete cds.

EXAMINER

R. E. Ferrell

DATE CONSIDERED 2/14/01

Inf 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group 1632

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C29	Genbank Accession No. U73620 (Locus MMU73620) Mus musculus VEGF-C mRNA, complete cds.
C30	Genbank Accession No. P35917, Vascular Endothelial Growth Factor Receptor 3 Precursor (VEGFR-3) (Tyrosine-Protein Kinase Receptor FLT4).
C31	Genbank Accession No. S66407, FLT4 = receptor tyrosine kinase isoform FLT4 long {3' region, alternatively spliced} [human, mRNA Partial, 216 nt].
C32	Genbank Accession No. X68203, H. sapiens mRNA for FLT4, class III receptor tyrosine kinase.
C33	<i>Genetic variants and strains of the laboratory mouse</i> , 2nd ed., New York: Oxford University Press, p. 70 (1989).
C34	Gnatenko <i>et al.</i> , "Characterization of Recombinant Adeno-Associated Virus-2 as a Vehicle for Gene Delivery and Expression into Vascular Cells," <i>J. Invest. Med.</i> , 45: 87-98 (1997).
C35	Greenlee <i>et al.</i> , "Developmental Disorders of the Lymphatic System," <i>Lymphology</i> , 26:156-168 (1993).
C36	Holmes <i>et al.</i> , "Hereditary Late-Onset Lymphedema," <i>Pediatrics</i> 61:575-579 (1978).
C37	Isner <i>et al.</i> , "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> , 91: 2687-2692 (1995).
C38	Isner <i>et al.</i> , "Arterial Gene Therapy for Restenosis," <i>Human Gene Therapy</i> , 7: 989-1011 (May, 1996).
C39	Jabs <i>et al.</i> , "A Mutation in the Homeodomain of the Human MSX2 Gene in a Family Affected with Autosomal Dominant Craniosynostosis," <i>Cell</i> , 75:443-450 (November, 1993).
C40	Jeltsch <i>et al.</i> , "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," <i>Science</i> , 276:1423-1425 (May, 1997).
C41	Joukov <i>et al.</i> , "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," <i>EMBO J.</i> , 15:290-298 (1996).

EXAMINER

E. L. Smith

DATE CONSIDERED

2/4/01

Inf 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group 1632

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C42	Joukov <i>et al.</i> , "Proteolytic Processing Regulates Receptor Specificity and Activity of VEGF-C," <i>EMBO J.</i> , 16(13): 3898-3911 (1997).
C43	Joukov <i>et al.</i> , "A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities," <i>J. Biol. Chem.</i> , 273(12): 6599-6602 (March, 1998).
C44	Jussila <i>et al.</i> , "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Receptor-3," <i>Cancer Res.</i> , 58: 1599-604 (April, 1998).
C45	Kaipainen, A., <i>et al.</i> , "Expression of the fms-like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," <i>Proc. Natl. Acad. Sci., USA</i> , 92: 3566-3570 (April, 1995).
C46	Kieleczawa <i>et al.</i> , "DNA Sequencing by Primer Walking with Strings of Contiguous Hexamers," <i>Science</i> , 258:1787-1791 (December, 1992).
C47	Kim <i>et al.</i> , "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1," <i>J. Virol.</i> , 72(1): 811-816 (January, 1998).
C48	Kingsman, A. & Johnson, E., "A New Generation of Gene Therapy Vectors," <i>Scrip Magazine</i> , pp. 43-46 (October 1998).
C49	Kinmonth, J.B., in Kinmonth, J.B. (ed), <i>The Lymphatics: Diseases, Lymphography and Surgery</i> . Edward Arnold Publishers: London, England (1972), pp. 82-86
C50	Korhonen <i>et al.</i> , "Endothelial-Specific Gene Expression Directed by the <i>tie</i> Gene Promoter In Vivo," <i>Blood</i> , 86(5): 1828-1835 (1995).
C51	Kukk <i>et al.</i> , "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development," <i>Development</i> , 122: 3829-3837 (1996).
C52	Lehner <i>et al.</i> , "Comparative Sequence Analysis of Human Cytomegalovirus Strains," <i>J. Clin. Microbiol.</i> , 29:2494-2502 (November, 1991).
C53	Levinson, K.L., "Linkage Analysis of Hereditary Lymphedema to Chromosome 5: Preliminary Analysis for a Genome Scan," Submitted to the Graduate Faculty of the Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science, University of Pittsburgh, pp. ii-vii and 1-54 (1996).

EXAMINER

DATE CONSIDERED

2/14/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999Group
1632

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C54	Lewis <i>et al.</i> , "Lymphedema praecox," <i>J. Ped.</i> , 104:641-648 (May, 1984).
C55	Lyon <i>et al.</i> , "Research News," <i>Mouse News Lett.</i> 71: 26 (1984).
C56	Maxam <i>et al.</i> , "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages," <i>Meth. Enzymol.</i> , 65: 499-560 (1977).
C57	Miller <i>et al.</i> , "A Simple Salting Out Procedure for Extracting DNA from Human Nucleated Cells," <i>Nucleic Acids Res.</i> , 16: 1215 (1988).
C58	Milroy, W.F., "An Undescribed Variety of Hereditary Edema," <i>N.Y. Medical J.</i> , 56:505-508 (1892).
C59	Mirzabekov, A.D., "DNA Sequencing by Hybridization - a Megasequencing Method and a Diagnostic Tool?" <i>TIBTECH</i> , 12: 27-32 (January, 1994).
C60	Mohammadi <i>et al.</i> , "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism," <i>Cell</i> , 86:577-587 (August, 1996).
C61	Lyon <i>et al.</i> , in: <i>Mouse News Lett.</i> 74: 96 (1986).
C62	Myers <i>et al.</i> , "Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA: DNA Duplexes," <i>Science</i> , 230: 1242-1246 (1985).
C63	O'Connell, J.R. <i>et al.</i> , "PedCheck: A Program for Identifying Marker Typing Incompatibilities in Linkage Analysis," D.E., <i>Am. J. Hum. Genet.</i> , 61:A288 (1997) (ABSTRACT).
C64	O'Connell, J.R. <i>et al.</i> , "The VITESSE Algorithm for Rapid Exact Multilocus Linkage Analysis Via Genotype Set-Recoding and Fuzzy Inheritance," <i>Nature Genet.</i> , 11:402-408 (December, 1995).
C65	Offori <i>et al.</i> , "Angiosarcoma in Congenital Hereditary Lymphoedema (Milroy's Disease) - Diagnostic Beacons and a Review of the Literature," <i>Clin. Exp. Dermatol.</i> , 18:174-177 (1993).
C66	Oh <i>et al.</i> , "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," <i>Dev. Biol.</i> , 188:96-109 (1997).
C67	Ohkuma, M., "Dermal Lymph and Lymphatics," in <i>Lymph Stasis: Pathophysiology, Diagnosis and Treatment</i> , Chapter 7, CRC Press, Boca Raton, FL, pp. 157-189 (1991).

EXAMINER

DATE CONSIDERED

2/14/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)


U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group 1632

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C68	Olszewski, W.L., "Chemistry of Lymph," in <i>Lymph Stasis: Pathophysiology, Diagnosis, and Treatment</i> , Chapter 10, CRC Press, Boca Raton, FL, pp. 235-258 (1991).
C69	Orita <i>et al.</i> , "Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms," <i>Proc Natl. Acad. Sci., USA</i> , 86: 2766-2770 (April, 1989).
C70	Ott, J., "Computer-simulation Methods in Human Linkage Analysis," <i>Proc. Nat. Acad. Sci., USA</i> , 86:4175-4178 (June, 1989).
C71	Pajusola <i>et al.</i> , "FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin-Like Loops and Is Expressed in Multiple Human Tissues and Cell Lines," <i>Cancer Res.</i> , 52:5738- 5743 (October, 1992).
C72	Pajusola <i>et al.</i> , "Two Human FLT4 Receptor Tyrosine Kinase Isoforms with Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," <i>Oncogene</i> 8: 2931-2937 (1993).
C73	Pajusola <i>et al.</i> , "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related to Two VEGF Receptors," <i>Oncogene</i> , 9: 3545-3555 (1994).
C74	Partanen <i>et al.</i> , "Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for <i>Fgfr1</i> in anteroposterior patterning of mouse embryos," <i>Genes & Development</i> , 12: 2332-2344 (1998)
C75	Pastinen <i>et al.</i> , "Minisequencing: A Specific Tool for DNA Analysis and Diagnostics on Oligonucleotide Arrays," <i>Genome Res.</i> , 7: 606-614 (1997).
C76	Patterson <i>et al.</i> , "Hereditary Lymphedema," <i>Comparative Pathology Bulletin</i> , 3: 2 (May, 1971).
C77	Paulsson <i>et al.</i> , "The Balbiani Ring 3 Gene in Chironomous tentans has a Diverged Repetitive Structure Split by Many Introns," <i>J. Mol. Biol.</i> , 211:331-49 (1990).
C78	Pease <i>et al.</i> , "Light-generated Oligonucleotide Arrays for Rapid DNA Sequence Analysis," <i>Proc. Natl. Acad. Sci., USA</i> , 91:5022-5026 (May, 1994).
C79	Quantin <i>et al.</i> , "Adenovirus as an Expression Vector in Muscle Cells <i>in Vivo</i> ," <i>Proc. Natl. Acad. Sci., USA</i> , 89:2581-2584 (April, 1992).

EXAMINER

K. Ferrell

DATE CONSIDERED

2/14/01

Jef 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

28967/35255A

Serial No.

09/375,248

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant


Ferrell, R.E. *et al.*

Filing Date

August 16, 1999

Group

1632



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C80	Ramsay, G., "DNA Chips: State-of -the-Art," <i>Nature Biotechnology</i> , 16: 40-48 (January, 1998).
C81	Riesner <i>et al.</i> , "Temperature-gradient Gel Electrophoresis of Nucleic Acids: Analysis of Conformational Transitions, Sequence Variations, and Protein-Nucleic acid Interactions," <i>Electrophoresis</i> , 10: 377-389 (1989).
C82	Roberts <i>et al.</i> , "Potassium Permanganate and Tetraethylammonium Chloride are a Safe and Effective Substitute for Osmium Tetroxide in Solid-Phase Fluorescent Chemical Cleavage of Mismatch," <i>Nucl. Acids Res.</i> , 25: 3377-3378 (1997).
C83	Rosenfeld <i>et al.</i> , "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," <i>Cell</i> , 68: 143-155 (January, 1992).
C84	Rowley <i>et al.</i> , "Ultrarapid Mutation Detection by Multiplex Solid-Phase Chemical Cleavage," <i>Genomics</i> , 30: 574-582 (1995).
C85	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> (Second ed., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989) §§ 9.47-9.51.
C86	Sanger <i>et al.</i> , "DNA Sequencing With Chain-Terminating Inhibitors," <i>Proc. Natl. Acad. Sci. (USA)</i> , 74:5463-5467 (December, 1977).
C87	Schafer <i>et al.</i> , "DNA Variation and the Future of Human Genetics," <i>Nature Biotechnology</i> , 16: 33-39 (1998).
C88	Drmanac, R. <i>et al.</i> , "DNA sequence determination by hybridization: a strategy for efficient large-scale sequencing," [published erratum appears in <i>Science</i> 1994 Feb 4; 163(5147):596] <i>Science (UNITED STATES)</i> , 260(5114):1649-52 (June, 1993).
C89	Shumaker <i>et al.</i> , "Mutation Detection by Solid Phase Primer Extension," <i>Human Mutation</i> , 7: 346-354 (1996).
C90	Stratford-Perricadet <i>et al.</i> , "Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart," <i>J. Clin. Invest.</i> , 90: 626-630 (August, 1992).
C91	Thompson <i>et al.</i> , "The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis," <i>Dev. Biol.</i> , 197(2):248-269 (May, 1998).

EXAMINER

E. Lowell

DATE CONSIDERED

2/14/01
Jefc2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35255ASerial No.
09/375,248

INFORMATION DISCLOSURE STATEMENT

Applicant
Ferrell, R.E. *et al.*Filing Date
August 16, 1999

Group 1632

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C92	Tsurumi, Y. <i>et al.</i> , "Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion," <i>Circulation</i> , 34:3281-3290 (1996).
C93	Tsurumi, Y. <i>et al.</i> , "Treatment of Acute Limb Ischemia by Intramuscular Injection of Vascular Endothelial Growth Factor Gene," <i>Circulation</i> , 96(Suppl. II):II-382-II-388 (1997).
C94	Uhley, H. and Leeds, S., "Pulmonary Lymph and Lymphatics," in <i>Lymph Stasis: Pathophysiology, Diagnosis and Treatment</i> , Chapter 8, CRC Press, Boca Raton, FL, pp. 191-209 (1991).
C95	Van Der Geer <i>et al.</i> , "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," <i>Ann. Rev. Cell. Biol.</i> , 10:251-337 (1994).
C96	van der Putte, "Congenital Hereditary Lymphedema in the Pig," <i>Lympho</i> , 11: 1-9 (1978).
C97	Weeks <i>et al.</i> , "SLINK: A General Simulation Program for Linkage Analysis," <i>Am. J. Hum. Genet.</i> , 47:A204 (1990) (ABSTRACT).
C98	Wheeler <i>et al.</i> , "Familial Lymphedema Praecox: Meige's Disease," <i>Plastic Reconstructive Surg.</i> , 67:362-364 (1981).
C99	White <i>et al.</i> , "Detecting Single Base Substitutions as Heteroduplex Polymorphisms," <i>Genomics</i> , 12: 301-306 (1992).
C100	Witte <i>et al.</i> , "Phenotypic and genotypic heterogeneity in familial Milroy lymphedema," <i>Lymphology</i> , 31(4):145-155 (December, 1998).
C101	Yin <i>et al.</i> , "Genomic Structure of the Human KDR/flk-1 Gene," <i>Mammalian Genome</i> , 9: 408-410 (1998).

EXAMINER

F. Salas

N

DATE CONSIDERED

2/4/01

Jef 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.